Results 191 to 200 of about 38,272 (314)

Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study [PDF]

, 2023
Lauren K. Park, Kian‐Huat Lim, J. L. Volkman, Mina Abdiannia, Hannah Johnston, Zack Nigogosyan, Marilyn J. Siegel, Janet B. McGill, Alexis M. McKee, Maamoun Salam, Rong M. Zhang, Da Ma, Karteek Popuri, Vincent Chow, Mirza Faisal Beg, William G. Hawkins, Linda R. Peterson, Joseph E. Ippolito   +17 more
openalex   +1 more source

Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes [PDF]

, 2016
Jeffrey Stephens
core   +1 more source

IDF21-0387 Efficacy of Dapagliflozin and Its Role on Microalbuminuria: Multicentric Real World Evidence from Pakistan [PDF]

, 2022
M.U. Wahab, S. Kalra, U. Aisha, U.Y. Raja, I. Ahmad   +4 more
openalex   +1 more source

Impact of Dapagliflozin on Atherosclerosis through Inflammation and Oxidative Pathways [PDF]

Zainab Abdlkadhim Aboshnin, Safa Azhar Razzaq, Zahraa Ibraheim   +2 more
openalex   +1 more source

Comparative study on the cardioprotective effects against ischemia/reperfusion injury of the selective SGLT2 inhibitors, empagliflozin, dapagliflozin and ertugliflozin in non-diabetic mice [PDF]

, 2021
Nikolaos Mylonas, Panagiota Nikolaou, Panagiotis Efentakis, George Dimitriadis, Efstathios K. Iliodromitis, Ioanna Andreadou   +5 more
openalex   +1 more source

Effects of a Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin on Pancreas in Obese Diabetic Mice. [PDF]

In Vivo
Sekikawa R, Uehara H, Uno K, Sasase T, Nakata Y, Mori Y, Shinohara M, Sugimoto M, Ohta T.   +8 more
europepmc   +1 more source

Dapagliflozin [PDF]

Drugs in R & D, 2010
openaire   +1 more source

Incidence of Diabetic Ketoacidosis in Dapagliflozin-Treated Japanese Patients With Type 1 Diabetes Mellitus: An Observational Cohort Database Study. [PDF]

Pharmacoepidemiol Drug Saf
Tamura R, Kim H, Takumi Y, Ishihara M, Kobayashi T, Layton D, Sakamoto K.   +6 more
europepmc   +1 more source

SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes? [PDF]

, 2016
Wilding, John
core   +1 more source

Development and optimization of dapagliflozin oral nano-bilosomes using response surface method: in vitro evaluation, in vivo evaluation [PDF]

Ananda Kumar Chettupalli, Nihar Ranjan Kar, V T Iswariya, Uttam Prasad Panigrahy, Laliteshwar Pratap Singh, Harekrishna Roy, Deepadarshan Urs, V. S. Muralidharan, Sandhya Rani Mandadi, M. Akiful Haque, Ritesh Rana, Talha Bin Emran   +11 more
openalex   +1 more source